172 related articles for article (PubMed ID: 10206077)
1. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).
Addis A; Loebstein R; Koren G; Einarson TR
Eur J Clin Pharmacol; 1999 Mar; 55(1):1-6. PubMed ID: 10206077
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
[TBL] [Abstract][Full Text] [Related]
3. A trial of deferiprone in transfusion-dependent iron overloaded children.
Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M
Ceylon Med J; 2000 Jun; 45(2):71-4. PubMed ID: 11051705
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
Gomber S; Saxena R; Madan N
Indian Pediatr; 2004 Jan; 41(1):21-7. PubMed ID: 14767084
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
6. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
7. Deferiprone as an oral iron chelator in sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Chuansumrit A; Songdej D; Sirachainan N; Wongwerawattanakoon P; Kadegasem P; Sasanakul W
Paediatr Int Child Health; 2016 Aug; 36(3):209-13. PubMed ID: 26052612
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
Cohen AR; Galanello R; Piga A; De Sanctis V; Tricta F
Blood; 2003 Sep; 102(5):1583-7. PubMed ID: 12763939
[TBL] [Abstract][Full Text] [Related]
11. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
12. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
[TBL] [Abstract][Full Text] [Related]
13. Experience with the oral iron chelator deferiprone in transfusion-dependent children.
Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M; Karunatilaka DH; Weerasinghe I
Ceylon Med J; 2002 Dec; 47(4):119-21. PubMed ID: 12661341
[TBL] [Abstract][Full Text] [Related]
14. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
15. A risk-benefit assessment of iron-chelation therapy.
Porter JB
Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
[TBL] [Abstract][Full Text] [Related]
16. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B
Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
18. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with deferiprone and desferrioxamine.
Wonke B; Wright C; Hoffbrand AV
Br J Haematol; 1998 Nov; 103(2):361-4. PubMed ID: 9827905
[TBL] [Abstract][Full Text] [Related]
20. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
